Abstract Number: 6L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab, an Interleukin 12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Results of a Phase 2, Randomized Placebo-Controlled Study
Background/Purpose: The IL-12/23 pathway has been implicated in the pathogenesis of SLE. The anti-IL12/23 monoclonal antibody ustekinumab (UST) is efficacious in the treatment of psoriasis,…Abstract Number: 471 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?
Background/Purpose: Patients with rheumatoid arthritis (RA) may fail to respond to biologic therapy. We study patients who are resistant to different classes of biologic agents…Abstract Number: 1158 • 2017 ACR/ARHP Annual Meeting
Treatment of Non-Infectious Uveitis: A Comparative Long-Term Study between Biologic Therapy with Adalimumab and Two Conventional Disease-Modifying Antirheumatic Drugs
Background/Purpose: Uveitis are inflammatory processes of the vascular layer of the eye, the uvea, which is divided into iris (anterior uvea), ciliary body (intermediate) and…Abstract Number: 1541 • 2017 ACR/ARHP Annual Meeting
First Line Biological Treatment in Ankylosing Spondylitis, Prescription Rates, Baseline Demographics and Disease Activity. a Collaboration between Biological Registers in the Five Nordic Counties
Background/Purpose: Large-scale observational cohorts identified in national biological registries may be used to study effectiveness of biological disease modifying drugs (bDMARDs) in ankylosing spondylitis (AS).…Abstract Number: 2409 • 2017 ACR/ARHP Annual Meeting
Older Age and Male Gender Are Independent Predictors of Quantiferon Positivity Among Adult Rheumatic Patients in a Tertiary Care Center from a BCG Vaccinated Country: Hur-BIO Single Center Real Life Results
Background/Purpose: TNF-α inhibitors increase the risk of emergence of active tuberculosis (TB). Screening rheumatic patients for latent TB is a necessity before initiation of biological…Abstract Number: 475 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patient Characteristics Also Predict Response to Therapy with Biologic Agents: Results from the Corrona Certain Study
Background/Purpose: Response to biologic agents approved for RA may be associated with patient reported factors that are not related to disease and usually not included…Abstract Number: 1425 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Patients with Rheumatoid Arthritis Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Background/Purpose: Many treatment options are currently available to patients with rheumatoid arthritis (RA), including tumor necrosis factor inhibitors (TNFi’s). While combination therapy of TNFi’s or…Abstract Number: 1542 • 2017 ACR/ARHP Annual Meeting
Inequity in Biologic DMARD Prescription for Spa across the Globe: Results from the Multi-Centre, Cross-Sectional, ASAS Comospa Study
Background/Purpose: The value of biologic DMARDs (bDMARDs) in SpA is well recognized but global access to these treatments can be limited due to high cost…Abstract Number: 2444 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Safety of CT-P13 in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Plaque Psoriasis: Observational Study in Republic of Korea
Background/Purpose: CT-P13 is approved as a biosimilar of innovator infliximab for marketing in 81 countries. After approval, observational study has been conducted in Republic of…Abstract Number: 521 • 2017 ACR/ARHP Annual Meeting
Update on the Clinical Phase 1 and Phase 2 Trials Investigating the Fully Human Immunocytokine Dekavil (F8IL10) in Patients with Rheumatoid Arthritis
Background/Purpose: The antibody-based targeted pharmacodelivery of cytokines by means of immunocytokines has the potential to enhance therapeutic activity at the site of disease while sparing…Abstract Number: 1430 • 2017 ACR/ARHP Annual Meeting
Switching from Synthetic to Biologic Dmards – Is There an Insufficient Use of Methotrexate?
Background/Purpose: A recent US-study suggests considerable underuse of MTX and too early switches to biologic (b)DMARDs1 before using a high MTX dose or changing the…Abstract Number: 1543 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness of TNF Inhibition in Spondyloarthritis. Data from a Large Nationwide Prospective Cohort – the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis
Background/Purpose: TNF inhibition has revolutionised the treatment of axial spondyloarthritis (AxSpA). Much of what we know about the use of these drugs comes from randomised…Abstract Number: 2447 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Tolerability of Benepali in Rheumatoid Arthritis Patients Switched from Enbrel
Background/Purpose: Benepali, the etanercept biosimilar, is licenced in the UK for rheumatoid arthritis (RA) and costs less than Enbrel. This study aimed to evaluate the…Abstract Number: 523 • 2017 ACR/ARHP Annual Meeting
Prevalence of Occult Hepatitis B Carrier Status and Its Associated Risk Factors in Patients with Rheumatic Diseases Undergoing Biological Therapies
Background/Purpose: To study the prevalence of occult hepatitis B carrier status and its associated factors in patients with rheumatic diseases undergoing biological therapies Methods: Consecutive…Abstract Number: 1439 • 2017 ACR/ARHP Annual Meeting
Factors Influencing the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting. Pooled Analysis of 2 Observational Studies
Background/Purpose: Tocilizumab (TCZ) as monotherapy (Mono) is nowadays a standard treatment in rheumatoid arthritis (RA) for patients in whom methotrexate (MTX) gives an inadequate response1.…
- 1
- 2
- 3
- …
- 21
- Next Page »